Antinociceptive tolerance to NSAIDs in the agranular insular cortex is mediated by opioid mechanism

Natia Pirkulashvili¹
Nana Tsiklauri¹
Marina Nebieridze²
Merab G Tsagareli¹

¹Laboratory of Pain and Analgesia, ²Laboratory of Brain Metabolism, Beritashvili Center for Experimental Biomedicine, Tbilisi, Georgia

Abstract: Several lines of investigations have shown that in some brain areas, in particular, in the midbrain periaqueductal gray matter, rostral ventromedial medulla, central nucleus of amygdala, nucleus raphe magnus, and dorsal hippocampus, microinjections of nonsteroidal anti-inflammatory drugs (NSAIDs) induce antinociception with distinct development of tolerance. The agranular insular cortex (AIC) is a small region of the cerebral cortex located on the lateral area of the rat’s cerebral hemisphere that is involved in the perception and response to pain. In the present study, we investigated the development of tolerance to the analgesic effects of NSAIDs diclofenac, ketorolac, and xefocam microinjected into the AIC in rats. Male Wistar rats receiving NSAIDs into the AIC were tested for antinociception by tail-flick and hot plate tests. Treatment with each NSAID significantly enhanced the tail-flick and hot plate latencies on the first day, followed by a progressive decrease in the analgesic effect over a 4-day period, i.e., they developed tolerance. Pretreatment with an opioid antagonist naloxone completely prevented, and posttreatment naloxone abolished, the analgesic effects of the three NSAIDs in both behavioral assays. These findings support the notion that the development of tolerance to the antinociceptive effects of NSAIDs is mediated via an endogenous opioid system possibly involving descending pain modulatory systems.

Keywords: antinociception, endogenous opioids, descending modulation, nociception, non-opioid tolerance

Introduction

A growing body of literature suggests that the brain region that is a part of the pain processing network, the insula, is both anatomically and functionally well suited to serve a primary and fundamental role in pain processing. By quantitative perfusion neuroimaging to investigate slowly varying neural states highly relevant to a complex phenomenon, such as pain, Segerdahl et al¹ identified the dorsal posterior insula as subserving a fundamental role in pain and as the likely human homologue of the nociceptive region identified from animal studies. Especially with regard to pain experience, the insular cortex has been presumed to participate in both sensory-discriminative and affective-motivational aspects of pain.²

The agranular insular cortex (AIC) is found in other mammals including cats, monkeys, and primates, including humans. In primates, the divisions of the insular cortex are the same as in rats, and the AIC occupies an area immediately noticeable, that is, dorsal to the primary olfactory cortex. The rat’s AIC is a small region of the cerebral cortex located on the lateral area of the cerebral hemisphere that is involved...
in the perception and response to pain. Direct injections of morphine into the AIC increase dopamine and GABA levels, resulting in behavioral antinociception. The major connections of the AIC are with areas that have established roles in behavior responses to nociceptive stimuli. The AIC projections to other cortical areas and subcortical sites such as the amygdala are likely to participate in the sensorimotor integration of nociceptive processing, while the hypothalamus and brainstem projections are most likely to contribute to descending pain inhibitory control.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used analgesics in the treatment of mild pain. For the last few years, however, it was established that repeated administration of NSAIDs systemically or in the midbrain periaqueductal gray matter (PAG) induced tolerance to these drugs, similar to opioid analgesics, and cross-tolerance to morphine.

We have recently shown that tolerance develops to analgesic effects of the commonly used NSAIDs (metamizol, diclofenac, ketorolac, and xefocam) given intraperitoneally in juvenile and adult rats in models of acute and chronic pain (the formalin test). We have also revealed that repeated microinjections of these nonopioids into the dorsal hippocampus (DH), the nucleus raphe magnus (NRM), and the central nucleus of amygdala (CeA) induce antinociception and the effects of tolerance and cross-tolerance to morphine.

In the present study, we hypothesized that the analgesic effects of the three NSAIDs, diclofenac, ketorolac, and xefocam microinjected into the AIC would exhibit antinociceptive tolerance mediated via endogenous opioids.

Materials and methods

Animals

The research was carried out on adult male Wistar rats weighing 200–250 g, bred at the Beritashvili Exp. BMC. The animals were kept under standard housing conditions (22°C±2°C, 65% humidity, and light from 7:00 a.m. to 8:00 p.m.) and kept on a standard dry diet with water freely available. Every effort was made to minimize both the number of animals used and their suffering. Six rats were used for each experimental and control group. The local Bioethical Committee of the Beritashvili Center for Experimental Biomedicine approved the experimental protocols, and we adhered to the Guidelines of the International Association for the Study of Pain regarding investigations of experimental pain in conscious animals.

Surgical procedures

Under anesthesia with intramuscular administration of ketamine (100 mg/kg, “KharkovPharm”, Ukraine), a 12-mm-long stainless steel guide cannula (Small Parts, Inc., Logansport, IN, USA) was stereotaxically implanted bilaterally into the rostral part of AIC, (AP: 2.70; L: ±4.4; H: 5.8) according to the coordinates in the atlas of Paxinos and Watson, sitting the tip 2 mm above the AIC. The guides were anchored to the cranium using dental cement. The guide cannula was plugged with a stainless steel stylet. Hereafter, the animals were handled every day for 3–4 days for 15–20 minutes to get familiar with the testing protocol and experimental environment. During this time, the stylet was removed and a 14-mm long stainless steel microinjection cannula was inserted into the guide cannula to reach the AIC, but no drug was injected. Five days after surgery, the microinjection cannula, attached to Hamilton syringe (Hamilton, Inc., McLean, VA, USA), was joined to the guide cannula, and the drug was introduced through it while the rat was gently restrained.

Drugs

Diclofenac (diclofenac sodium, 75 μg/0.5 μL, Hemo- farm, Vršac, Serbia), ketorolac (ketorolac tromethamine, 90 μg/0.5 μL, Grindex, Latvia), or xefocam (lornoxicam, 12 μg/0.5 μL, Nycomed, Zürich, Austria) were injected through the microinjection cannula as used in previous works. The guide cannula was then plugged with a stainless steel stylet. Isotonic saline was injected in the same volume (0.5 μL, GalichPharm, Ukraine) and manner in a separate group of rats, treated as controls. In the second set of experiments, a nonselective opioid receptor antagonist naloxone (0.2 μg/0.5 μL, Polfa S.A., Poland) was injected through the microinjection cannula. Solutions were microinjected in about 10–12 seconds.

Behavioral testing

Twenty minutes after microinjection of NSAIDs or saline, ie, 10 minutes before the peak of the drugs’ effect is normally reached, rats were tested for antinociception using the tail-flick (TF) and hot plate (HP) tests. For the TF test, the distal part of the tail was stimulated with a light beam and the latency measured until the tail was reflexively flicked away from the beam (IITC #33, IITC Life Science, Inc., Woodland Hills, CA, USA). For the HP test, the rat was placed on a 55°C hot plate and the latency to the first hindpaw lick or time to first jump was measured (IITC #39). The cut off time was 20s for both TF and HP latencies. Each animal was tested with...
both TF and HP tests in the same session. A similar procedure was followed for the repeated microinjection of diclofenac, ketorolac, xefocam, or saline for four consecutive days.

In the second set of experiments, pretreatment of rats with naloxone in the AIC was followed by TF and HP tests 10 minutes after they were treated with NSAIDs in the same dose as in the first set of experiments and were then retested again.

In the third set of experiments, posttreatment of rats with naloxone in the AIC was followed by TF and HP tests. For this purpose, 10 minutes prior to naloxone microinjections, rats were pretreated with NSAIDs in the same dose as in the first and second set of experiments and were then retested again. Different animal groups were used for the first, second, and third sets of experiments. The number of rats in each group was six.

**Histology**

At the end of each set of experiments, the microinjection sites were marked with 2 μL of saturated solution of Pontamine Sky Blue (Sigma-Aldrich, St. Louis, MO, USA) and the animal was euthanized with pentobarbital. After fixation by immersion in 10% formalin, the brain was sectioned and counterstained with Cresyl Violet. The microinjection sites were histologically verified and plotted according to Paxinos and Watson's stereotaxic atlas coordinates. Representative microinjection sites are shown in the Figure 1. However, we are aware that our histology needs more evidence for accuracy of the location of the injection sites, which limits the interpretation of the obtained data.

**Statistical analysis**

All mean control and experimental groups’ values are presented as mean ± standard error of mean. One-way analysis of variance (ANOVA) or repeated-measures ANOVA with post hoc Tukey–Kramer or Dunnett’s multiple comparison tests were used for statistical evaluation of comparisons between treated and saline groups and between treated and naloxone groups, respectively. The Kolmogorov–Smirnov test was applied to verify normality. The statistical software utilized was InStat 3.05 (GraphPad Software, San Diego, CA, USA). Differences between means of saline control and treated groups and between naloxone and treated groups of rats were acknowledged as statistically significant if $P<0.05$.

**Results**

**Tolerance to antinociceptive effects of NSAIDs**

In the first set of experiments, we found that microinjection of NSAIDs into the AIC produced antinociception, as revealed by a latency increase in the TF and HP compared to the baseline control of intact rats and a control group with saline microinjected into the same site. The repeated-measures ANOVA revealed that the TF latency significantly increased for clodifen [$F(9, 20) = 56.229, P<0.0001$], ketorolac

---

**Figure 1** Serial coronal sections of the rat brain showing placement of microinjections in the AIC (black arrows).


*Abbreviation:* AIC, agranular insular cortex.
[F(9, 20) = 30.398, P < 0.0001], and xefocam [F(9, 20) = 53.058, P < 0.0001], respectively, but not for saline group [F(9, 20) = 1.941, P = 0.1428, not significant]. On the first experimental day, the differences between NSAIDs-treated groups and the intact control group were significant for diclofenac (t = 18.549, P < 0.001), for ketorolac (t = 12.024, P < 0.001), and for xefocam (t = 17.696, P < 0.001), respectively (Figure 2A). The TF latency differences between NSAIDs-treated groups and the saline control group by Dunnett’s test were significant on the first experimental day for diclofenac (t = 4.940, P < 0.01), ketorolac (t = 2.541, P < 0.05), and xefocam (t = 5.733, P < 0.01), respectively.

We found similar significant differences of enhancement in the HP latencies compared to the intact group for diclofenac [F(9, 20) = 51.749, P < 0.0001], for ketorolac [F(9, 20) = 43.359, P < 0.0001], and for xefocam [F(9, 20) = 38.551, P < 0.0001], respectively, but not for saline control [F(9, 20) = 2.681, P = 0.0613, not significant]. Here also on the first experimental day, the differences between NSAIDs-treated groups and the intact control group were significant for clodifen (t = 16.989, P < 0.001), for ketorolac (t = 14.209, P < 0.001), and for xefocam (t = 15.488, P < 0.001), respectively (Figure 2B). The HP latency differences between NSAIDs-treated groups and the saline control group by Dunnett’s test were significant in the first experimental day for diclofenac (t = 6.938, P < 0.01), for ketorolac (t = 5.012, P < 0.01), and for xefocam (t = 7.580, P < 0.01).

Subsequent NSAIDs microinjections into the AIC caused gradually less antinociception, so by day 4 there was no effect, similar to saline microinjections for both the TF and the HP tests, i.e. induced tolerance (Figure 2). On the second experimental day, the TF latency differences between NSAIDs-treated groups and the saline control group by Dunnett’s test were significant for xefocam (t = 4.065, P < 0.01) and diclofenac (t = 3.090, P < 0.05), but not for ketorolac (t = 0.9749, P > 0.05, not significant). On the third and fourth experimental days, there were no significant differences between NSAIDs-treated groups and the saline control.

Concerning the HP test, on the second experimental day, the latency differences between NSAIDs-treated groups and the saline group by Dunnett’s test were significant for diclofenac (t = 4.534, P < 0.01), xefocam (t = 4.576, P < 0.01), and ketorolac (t = 2.899, P < 0.05), respectively. On the third day there, were significant differences for xefocam (t = 3.345, P < 0.01) and diclofenac (t = 3.002, P < 0.05), but not for ketorolac (t = 1.598, P > 0.05, not significant), while on the fourth day there were no significant differences for any of the NSAIDs.

**Pretreatment with naloxone prevents NSAIDs-induced antinociception**

In the second set of experiments, we tested if pretreatment with a nonselective opioid receptor antagonist naloxone prevents antinociception induced by NSAID microinjected into the AIC. Pretreatment with naloxone completely prevented the analgesic effects of diclofenac, ketorolac, and xefocam in the TF test. The ANOVA did not reveal significant differences between naloxone-injected and NSAIDs-injected groups for diclofenac [F(2, 15) = 0.6083, P = 0.2552, not significant], for ketorolac [F(2, 15) = 0.8998, P = 0.4275, not significant], and for xefocam [F(2, 15) = 3.078, P = 0.0758, not significant], respectively, and hence the TF latencies of the saline, naloxone, and NSAIDs groups were not significantly different when compared with the post hoc test (P > 0.05) (Figure 3A, C and E).
Similar results were observed in the HP test for diclofenac \(F(2,15)=0.8492, P=0.4473, \text{not significant}\), for ketorolac \(F(2,15)=0.3815, P=0.6893, \text{not significant}\), and for xefocam \(F(2,15)=0.6152, P=0.5536, \text{not significant}\), respectively, and hence the HP latencies of the saline, naloxone, and NSAIDs groups were not significantly different when compared with the post hoc test \(P>0.05\) (Figure 3B, D and F).

**Posttreatment with naloxone abolishes NSAIDs-induced antinociception**

In the third set of experiments, we tested if posttreatment with naloxone abolishes antinociception induced by NSAID microinjected into the AIC. We found that posttreatment with naloxone completely abolished the analgesic effects of diclofenac, ketorolac and xefocam in the TF test. The ANOVA revealed significant differences in the TF latencies between saline, NSAIDs, and naloxone groups for diclofenac \(F(2,15)=87.881, P<0.0001\), for ketorolac \(F(2,15)=89.175, P<0.0001\), and for xefocam \(F(2,15)=93.530, P<0.0001\), respectively. Naloxone completely abolished antinociceptive effects of diclofenac \(t=15.914, P<0.001\), ketorolac \(t=17.417, P<0.001\), and xefocam \(t=15.157, P<0.001\), respectively (Figure 4A, C and E).

Similar results we obtained in HP test. Here also, the ANOVA revealed significant differences in the HP latencies between saline, NSAIDs, and naloxone groups for diclofenac \(F(2,15)=86.529, P<0.0001\), ketorolac \(F(2,15)=39.425, P<0.0001\), and xefocam \(F(2,15)=114.22, P<0.0001\), respectively.

**Figure 3** Pretreatment with naloxone (0.2 μg/0.5 μL) before microinjections of NSAIDs into the AIC.

**Notes:** (A, C and E) Naloxone prevents NSAID-induced antinociception in TF latency for diclofenac (A), ketorolac (C), and xefocam (E), respectively. (B, D and F) Naloxone prevents NSAID-induced antinociception in HP latency for diclofenac (B), ketorolac (D), and xefocam (F), respectively. Statistical analysis was performed by one-way ANOVA with post hoc Tukey-Kramer’s multiple comparisons test; \(n=6\) per test group.

**Abbreviations:** AIC, agranular insular cortex; ANOVA, analysis of variance HP, hot plate; NSAIDs, nonsteroidal anti-inflammatory drugs; TF, tail-flick.
respectively. Opioid antagonist naloxone completely abolished analgesic effects of diclofenac \((t=15.503, P<0.001)\), ketorolac \((t=11.679, P<0.001)\), and xefocam \((t=17.022, P<0.001)\), respectively (Figure 4B, D and F).

**Discussion**

The present data have demonstrated that microinjections of commonly used NSAIDs, diclofenac, ketorolac and xefocam, into the AIC induce antinociception. These results are similar to the findings of previous investigations in an acute pain model with TF and HP tests, and in which metamizol, xefocam, ketorolac or lysine-acetylsalicylate were given systemically or microinjected into the PAG, the CeA and the NRM.\(^5,6,8,11,12,14,15,19,20\) In another study, responses of spinal dorsal horn wide-dynamic range neurons to mechanical noxious stimulation in hindpaw of rats were strongly inhibited by intravenous metamizol.\(^21\)

Moreover, repeated microinjections of these NSAIDs into the AIC over a period of 4 days resulted in development of tolerance due to a progressive decrease in antinociceptive effectiveness, reminiscent of that usually induced by opiates.\(^5,7,8,12,22\) These findings confirm our previous results in which development of tolerance was observed to the analgesic effects of diclofenac, ketorolac and xefocam microinjected.
into the DH of rats. After administration of each NSAID, a progressive decrease in TF and HP latency (ie, tolerance) was noticed over the 4-day period.13,20

According to the recently established concept, the mechanism producing tolerance to NSAIDs can be due to involvement of endogenous opioid peptides.8,16,23,24 In this study, we have clearly shown that pre- and posttreatment of a nonselective opioid receptor antagonist naloxone significantly diminishes NSAIDs-induced antinociception. These findings confirm our previous evidence where NSAIDs antinociception in the DH was reduced by pretreatment as well as posttreatment with naloxone.13,20 We have just recently showed that systemic pretreatment with naloxone completely prevented the analgesic effects of intraperitoneally injected NSAIDs, in thermal paw withdrawal and mechanical paw withdrawal tests in the formalin model of pain.25

All presented data confirm the other results that antinociception induced by systemic metamizol involves endogenous opioids that can be blocked by naloxone at the levels of the PAG, the NRM and the spinal dorsal horn, as well as findings that endogenous opioids are involved in the potentiation of analgesia observed with a combination of morphine plus dipyrone.26,27 These data support a role for endogenous opioidergic descending pain-control circuits. The latter consists of the brainstem pain modulatory PAG–rostral ventromedial medulla axis underscoring the strong convergence of antinociceptive mechanisms for nonopioid and opioid analgesics.5,16,23,24,28

Conclusion
Overall, we showed for the first time that microinjections of diclofenac, ketorolac, and xefocam, commonly used NSAID analgesics, into the AIC, induce antinociception in rats. Repeated administration leads to tolerance development to these drugs. The present data support the notion that the development of tolerance to the antinociceptive effects of NSAIDs is mediated via an endogenous opioid system, possibly involving descending pain modulatory systems. Nevertheless, future experimental trials with clear histology of the location of the injections should be cognizant of this antinociceptive tolerance phenomenon in the AIC in assessing treatment responses as well as probing underlying mechanisms.

Acknowledgment
We would like to thank Ms N Skhirtladze for her English editing of the manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References


